Genetic variation in the natriuretic peptide system and heart failure.
Heart failure (HF) is a modern epidemic and is one of the few cardiovascular diseases which is increasing in prevalence. The growing importance of the Natriuretic Peptide (NP) system in HF is well recognized. Laboratory tests for B-type Natriuretic Peptide (BNP) have proven value as diagnostic and prognostic tools in HF and are now part of routine clinical care. Furthermore, recombinant atrial natriuretic peptide (ANP) (carperitide) and BNP (nesiritide) and are approved HF therapies in Japan and the US, respectively and additional natriuretic peptides (e.g., CNP, urodilatin, and designer NPs) are under investigation for use in HF. Common genetic sequence variants are increasingly being recognized as determinants of disease risk or drug response and may help explain a portion of the inter-individual variation in the human NP system. This review describes current knowledge of NP system genetic variation as it pertains to HF as well as ongoing studies and where the field is expected to progress in the near future. To briefly summarize, NP system genetic variants have been associated with alterations in gene expression, NP levels, and cardiovascular disease. The next step forward will include specific investigations into how this genetic variation can advance 'Personalized Medicine', such as whether they impact the utility of diagnostic BNP testing or effectiveness of therapeutic NP infusion. This is already in progress, with pharmacogenetic studies of nesiritide currently underway. We expect that within 5 years there should be a reasonable idea of whether NP system genetic variation will have important clinical implications.
Lanfear
David E
DE
Henry Ford Heart and Vascular Institute, Section of Advanced Heart Failure and Cardiac Transplantation, Henry Ford Hospital, 2799 W. Grand Boulevard, K14, Detroit, MI 48202, USA. dlanfea1@hfhs.org
D009320:Atrial Natriuretic Factor / Q000235:genetics; D014644:Genetic Variation; D006333:Heart Failure / Q000188:drug therapy / Q000235:genetics*; D006801:Humans; D020097:Natriuretic Peptide, Brain / Q000235:genetics; D045265:Natriuretic Peptides / Q000235:genetics*; D010597:Pharmacogenetics; D015995:Prevalence; D011379:Prognosis; D017461:Receptors, Atrial Natriuretic Factor / Q000235:genetics; D012307:Risk Factors; D016896:Treatment Outcome
D045265:Natriuretic Peptides; D020097:Natriuretic Peptide, Brain; D009320:Atrial Natriuretic Factor; D017461:Receptors, Atrial Natriuretic Factor; C091715:atrial natriuretic factor receptor A